Publications

• Exploring study dropout in drug trials for adults with PTSD: insights from a conventional and individual participant data meta-analysis.
  Eur J Psychotraumatol Volume: 16 Page(s): 2504839
  12/01/2025 Authors: Wright SL; Kessler A; Sijbrandij M; Karyotaki E; Cuijpers P; Bisson J; Brady K; Dowd SM; Dunlop BW; Pollack MH
• A Systematic Review to Determine if Family History of Response to Medication Predicts Outcome in Mood Disorders.
  J Clin Psychopharmacol Volume: 45 Page(s): 364 - 371
  07/01/2025 Authors: Rakofsky JJ; Lucido MJ; Dunlop BW
• Medication use is associated with distinct microbial features in anxiety and depression.
  Mol Psychiatry Volume: 30 Page(s): 2545 - 2557
  06/01/2025 Authors: Dilmore AH; Kuplicki R; McDonald D; Kumar M; Estaki M; Youngblut N; Tyakht A; Ackermann G; Blach C; MahmoudianDehkordi S
• Metabolomics signatures of serotonin reuptake inhibitor (escitalopram), serotonin norepinephrine reuptake inhibitor (duloxetine) and cognitive-behavioral therapy on key neurotransmitter pathways in major depressive disorder.
  J Affect Disord Volume: 375 Page(s): 397 - 405
  04/15/2025 Authors: Bhattacharyya S; MahmoudianDehkordi S; Sniatynski MJ; Belenky M; Marur VR; Rush AJ; Craighead WE; Mayberg HS; Dunlop BW; Kristal BS
• The Metabolomic Signature of Childhood Trauma.
  Biol Psychiatry
  04/04/2025 Authors: Souama C; Lamers F; Milaneschi Y; Jansen R; Vinkers CH; Giltay EJ; Dunlop BW; Kaddurah-Daouk R; Penninx BWJH; Mood Disorder Precision Medicine Consortium
• Results From a Long-Term Observational Follow-Up Study of a Single Dose of Psilocybin for a Treatment-Resistant Episode of Major Depressive Disorder.
  J Clin Psychiatry Volume: 86
  03/03/2025 Authors: Goodwin GM; Nowakowska A; Atli M; Dunlop BW; Feifel D; Hellerstein DJ; Marwood L; Shabir Z; Mistry S; Stansfield SC
• The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression.
  J Affect Disord Volume: 372 Page(s): 523 - 532
  03/01/2025 Authors: Goodwin GM; Aaronson ST; Alvarez O; Carhart-Harris R; Chai-Rees J; Croal M; DeBattista C; Dunlop BW; Feifel D; Hellerstein DJ
• Sustained effects of repeated levodopa (L-DOPA) administration on reward circuitry, effort-based motivation, and anhedonia in depressed patients with higher inflammation.
  Brain Behav Immun Volume: 125 Page(s): 240 - 248
  03/01/2025 Authors: Bekhbat M; Li Z; Dunlop BW; Treadway MT; Mehta ND; Revill KP; Lucido MJ; Hong C; Ashchi A; Wommack EC
• Prolonged adverse effects from repeated psilocybin use in an underground psychedelic therapy training program: a case report.
  BMC Psychiatry Volume: 25 Page(s): 184
  02/28/2025 Authors: Perna J; Trop J; Palitsky R; Bosshardt Z; Vantine H; Dunlop BW; Zarrabi AJ
• Acylcarnitines metabolism in depression: association with diagnostic status, depression severity and symptom profile in the NESDA cohort.
  Transl Psychiatry Volume: 15 Page(s): 65
  02/23/2025 Authors: Montanari S; Jansen R; Schranner D; Kastenmller G; Arnold M; Janiri D; Sani G; Bhattacharyya S; Mahmoudian Dehkordi S; Dunlop BW
• Emerging Medications for Treatment-Resistant Depression: A Review with Perspective on Mechanisms and Challenges.
  Brain Sci Volume: 15
  02/06/2025 Authors: Lucido MJ; Dunlop BW
• Prediction of individual patient outcomes to psychotherapy vs medication for major depression.
  Npj Ment Health Res Volume: 4 Page(s): 4
  02/05/2025 Authors: LoParo D; Dunlop BW; Nemeroff CB; Mayberg HS; Craighead WE
• The METEMP protocol: Massed exposure therapy enhanced with MDMA for PTSD.
  Contemp Clin Trials Commun Volume: 43 Page(s): 101400
  02/01/2025 Authors: Maples-Keller JL; Dunlop BW; Rothbaum BO
• A critical evaluation of psilocybin-assisted therapy protocol components from clinical trial patients, facilitators, and caregivers.
  Psychotherapy (Chic)
  01/13/2025 Authors: Palitsky R; Maples-Keller JL; Peacock C; Dunlop BW; Mletzko T; Grant GH; Raison CL; Chao S; Shub I; Mendelbaum-Kweller M
• Psychedelic Ethics in Palliative Care.
  Am J Bioeth Volume: 25 Page(s): 95 - 98
  01/01/2025 Authors: Davis K; Palitsky R; Dunlop BW; H Grant G; Zarrabi AJ
• Effect of agreement between clinician-rated and patient-reported PTSD symptoms on intensive outpatient treatment outcomes.
  Psychiatry Res Volume: 343 Page(s): 116287
  01/01/2025 Authors: Touponse SC; Guo Q; Ma T; Maples-Keller JL; Rothbaum BO; Dunlop BW
• Association of Bile Acids with Connectivity of Executive Control and Default Mode Networks in Patients with Major Depression.
  
  12/23/2024 Authors: Dunlop BW; Cha J; Mayberg HS; Choi KS; Edward Craighead W; MahmoudianDehkordi S; Bhattacharyya S; John Rush A; Kaddurah-Daouk R
• Leveraging meditation research for the study of psychedelic-related adverse effects.
  Int Rev Psychiatry Volume: 36 Page(s): 841 - 855
  12/01/2024 Authors: Palitsky R; Canby NK; Van Dam NT; Levin-Aspenson HF; Kaplan DM; Maples-Keller J; Raison CL; Grant GH; Dunlop BW; Britton WB
• The metabolome-wide signature of major depressive disorder.
  Mol Psychiatry Volume: 29 Page(s): 3722 - 3733
  12/01/2024 Authors: Jansen R; Milaneschi Y; Schranner D; Kastenmuller G; Arnold M; Han X; Dunlop BW; Mood Disorder Precision Medicine Consortium; Rush AJ; Kaddurah-Daouk R
• Rapid Effects of MDMA Administration on Self-Reported Personality Traits and Affect State: A Randomized, Placebo-Controlled Trial in Healthy Adults.
  J Psychoactive Drugs Page(s): 1 - 9
  10/23/2024 Authors: Maples-Keller JL; Hyatt CS; Phillips NL; Sharpe BM; Sherrill A; Yasinski C; Reiff C; Rakofsky J; Rauch SAM; Dunlop BW
• Acylcarnitines metabolism in depression: association with diagnostic status, depression severity and symptom profile in the NESDA cohort.
  Res Sq
  08/11/2024 Authors: Milaneschi Y; Montanari S; Jansen R; Schranner D; Kastenmller G; Arnold M; Janiri D; Sani G; Bhattacharyya S; Dehkordi SM
• A framework for assessment of adverse events occurring in psychedelic-assisted therapies.
  J Psychopharmacol Volume: 38 Page(s): 690 - 700
  08/01/2024 Authors: Palitsky R; Kaplan DM; Perna J; Bosshardt Z; Maples-Keller JL; Levin-Aspenson HF; Zarrabi AJ; Peacock C; Mletzko T; Rothbaum BO
• The capacity of brain circuits to enhance psychiatry.
  Nat Med Volume: 30 Page(s): 1834 - 1835
  07/01/2024 Authors: Dunlop BW; Mayberg HS
• The utility of measuring daily hassles and uplifts in understanding outcomes to treatments for major depressive disorder.
  Psychiatry Res Volume: 335 Page(s): 115859
  05/01/2024 Authors: Furman BW; Craighead WE; Mayberg HS; Mletzko T; Nemeroff CB; Dunlop BW
• Metabolomics Signatures of serotonin reuptake inhibitor (Escitalopram), serotonin norepinephrine reuptake inhibitor (Duloxetine) and Cognitive Behavior Therapy on Key Neurotransmitter Pathways in Major Depressive Disorder.
  medRxiv
  04/03/2024 Authors: Bhattacharyya S; MahmoudianDehkordi S; Sniatynski MJ; Belenky M; Marur VR; Rush AJ; Craighead WE; Mayberg HS; Dunlop BW; Kristal BS
• Medication Use is Associated with Distinct Microbial Features in Anxiety and Depression.
  bioRxiv
  03/19/2024 Authors: Dilmore AH; Kuplicki R; McDonald D; Kumar M; Estaki M; Youngblut N; Tyakht A; Ackermann G; Blach C; MahmoudianDehkordi S
• Acylcarnitines metabolism in depression: association with diagnostic status, depression severity and symptom profile in the NESDA cohort.
  medRxiv
  02/15/2024 Authors: Montanari S; Jansen R; Schranner D; Kastenmller G; Arnold M; Janiri D; Sani G; Bhattacharyya S; Dehkordi SM; Dunlop BW
• Neuroanatomical dimensions in medication-free individuals with major depressive disorder and treatment response to SSRI antidepressant medications or placebo.
  Nat Ment Health Volume: 2 Page(s): 164 - 176
  01/01/2024 Authors: Fu CHY; Antoniades M; Erus G; Garcia JA; Fan Y; Arnone D; Arnott SR; Chen T; Choi KS; Fatt CC
• Spiritual health practitioners' contributions to psychedelic assisted therapy: A qualitative analysis.
  PLoS One Volume: 19 Page(s): e0296071
  01/01/2024 Authors: Peacock C; Mascaro JS; Brauer E; Zarrabi AJ; Dunlop BW; Maples-Keller JL; Grant GH; Raison CL; Rab F; Palitsky R
• A Chart-Stimulated Recall Activity to Assess Psychiatry Residents' Treatment-Based, Clinical Reasoning Skills.
  Acad Psychiatry Volume: 47 Page(s): 663 - 666
  12/01/2023 Authors: Rakofsky JJ; Stoddard HA; Haroon E; Hermida AP; Debrey SM; Crowell AL; Dunlop BW
• Functional connectivity of salience and affective networks among remitted depressed patients predicts episode recurrence.
  Neuropsychopharmacology Volume: 48 Page(s): 1901 - 1909
  12/01/2023 Authors: Dunlop BW; Cha J; Choi KS; Nemeroff CB; Craighead WE; Mayberg HS
• Individuals with depression exhibiting a pro-inflammatory phenotype receiving omega-3 polyunsaturated fatty acids experience improved motivation-related cognitive function: Preliminary results from a randomized controlled trial.
  Brain Behav Immun Health Volume: 32 Page(s): 100666
  10/01/2023 Authors: Mac Giollabhui N; Mischoulon D; Dunlop BW; Kinkead B; Schettler PJ; Liu RT; Okereke OI; Lamon-Fava S; Fava M; Rapaport MH
• The Metabolome-Wide Signature of Major Depressive Disorder.
  Res Sq
  09/21/2023 Authors: Jansen R; Milaneschi Y; Schranner D; Kastenmuller G; Arnold M; Han X; Dunlop BW; Mood Disorder Precision Medicine Consortium; Rush AJ; Kaddurah-Daouk R
• Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial.
  JAMA Volume: 330 Page(s): 843 - 853
  09/05/2023 Authors: Raison CL; Sanacora G; Woolley J; Heinzerling K; Dunlop BW; Brown RT; Kakar R; Hassman M; Trivedi RP; Robison R
• Circulating metabolites modulated by diet are associated with depression.
  Mol Psychiatry Volume: 28 Page(s): 3874 - 3887
  09/01/2023 Authors: van der Spek A; Stewart ID; Khnel B; Pietzner M; Alshehri T; Gau F; Hysi PG; MahmoudianDehkordi S; Heinken A; Luik AI
• Psilocybin therapy for treatment resistant depression: prediction of clinical outcome by natural language processing.
  Psychopharmacology (Berl)
  08/22/2023 Authors: Dougherty RF; Clarke P; Atli M; Kuc J; Schlosser D; Dunlop BW; Hellerstein DJ; Aaronson ST; Zisook S; Young AH
• Omega-3 Fatty Acids for Depression: Recent Finding
  Volume: 79 Page(s): 280 - 280
  08/01/2023 Authors: Mischoulon D; Dunlop BW; Kinkead B; Schettler PJ; Lamon-Fava S; So J; Maddipati KR; Felger JC; Fava M; Rapaport MH
• The prescriber's guide to classic MAO inhibitors (phenelzine, tranylcypromine, isocarboxazid) for treatment-resistant depression.
  CNS Spectr Volume: 28 Page(s): 427 - 440
  08/01/2023 Authors: Van den Eynde V; Abdelmoemin WR; Abraham MM; Amsterdam JD; Anderson IM; Andrade C; Baker GB; Beekman ATF; Berk M; Birkenhger TK
• All studies are not created equal: A systematic narrative review of bipolar depression clinical trial inclusion/exclusion rules and baseline severity scores.
  J Affect Disord Volume: 333 Page(s): 130 - 139
  07/15/2023 Authors: Rakofsky JJ; Lucido MJ; Dunlop BW
• Importance of Integrating Spiritual, Existential, Religious, and Theological Components in Psychedelic-Assisted Therapies.
  JAMA Psychiatry Volume: 80 Page(s): 743 - 749
  07/01/2023 Authors: Palitsky R; Kaplan DM; Peacock C; Zarrabi AJ; Maples-Keller JL; Grant GH; Dunlop BW; Raison CL
• Balancing the beautiful and the good in pursuit of biomarkers for depression.
  World Psychiatry Volume: 22 Page(s): 265 - 267
  06/01/2023 Authors: Mayberg HS; Dunlop BW
• Clinical response to EPA supplementation in patients with major depressive disorder is associated with higher plasma concentrations of pro-resolving lipid mediators.
  Neuropsychopharmacology Volume: 48 Page(s): 929 - 935
  05/01/2023 Authors: Lamon-Fava S; Liu M; Dunlop BW; Kinkead B; Schettler PJ; Felger JC; Ziegler TR; Fava M; Mischoulon D; Rapaport MH
• Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life.
  J Affect Disord Volume: 327 Page(s): 120 - 127
  04/14/2023 Authors: Goodwin GM; Aaronson ST; Alvarez O; Atli M; Bennett JC; Croal M; DeBattista C; Dunlop BW; Feifel D; Hellerstein DJ
• Shared and Unique Changes in Brain Connectivity Among Depressed Patients After Remission With Pharmacotherapy Versus Psychotherapy.
  Am J Psychiatry Volume: 180 Page(s): 218 - 229
  03/01/2023 Authors: Dunlop BW; Cha J; Choi KS; Rajendra JK; Nemeroff CB; Craighead WE; Mayberg HS
• AI-based dimensional neuroimaging system for characterizing heterogeneity in brain structure and function in major depressive disorder: COORDINATE-MDD consortium design and rationale.
  BMC Psychiatry Volume: 23 Page(s): 59
  01/23/2023 Authors: Fu CHY; Erus G; Fan Y; Antoniades M; Arnone D; Arnott SR; Chen T; Choi KS; Fatt CC; Frey BN
• A preliminary descriptive report of the longevity of the effects of Swedish Massage therapy for subjects with Generalized Anxiety Disorder.
  J Bodyw Mov Ther Volume: 33 Page(s): 176 - 181
  01/01/2023 Authors: Rapaport MH; Schettler PJ; Larson ER; Edwards SA; Dunlop BW; Rakofsky JJ; Kinkead B
• Clinical Response to High-Dose Eicosapentaenoic Acid (EPA) Supplementation is Greater in MDD Patients Who Achieve Higher Plasma Concentrations of EPA-Derived Pro-Resolving Lipid Mediators
  Volume: 47 Page(s): 198 - 198
  12/01/2022 Authors: Lamon-Fava S; Liu M; Dunlop B; Kinkead B; Pamela S; Felger J; Ziegler T; Nierenberg A; Fava M; Mischoulon D
• Mapping the Peripheral Metabolome to Alterations in Functional Connectivity of Brain Networks in Major Depression
  Volume: 47 Page(s): 50 - 50
  12/01/2022 Authors: Dunlop B
• Assessing in-session rumination and its effects on CBT for depression.
  Behav Res Ther Volume: 159 Page(s): 104209
  12/01/2022 Authors: Kennedy JC; Dunlop BW; Craighead LW; Nemeroff CB; Mayberg HS; Craighead WE
• Rare copy number variation in posttraumatic stress disorder.
  Mol Psychiatry Volume: 27 Page(s): 5062 - 5069
  12/01/2022 Authors: Maihofer AX; Engchuan W; Huguet G; Klein M; MacDonald JR; Shanta O; Thiruvahindrapuram B; Jean-Louis M; Saci Z; Jacquemont S
• Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression.
  N Engl J Med Volume: 387 Page(s): 1637 - 1648
  11/03/2022 Authors: Goodwin GM; Aaronson ST; Alvarez O; Arden PC; Baker A; Bennett JC; Bird C; Blom RE; Brennan C; Brusch D
• Treatment efficacy and effectiveness in adults with major depressive disorder and childhood trauma history: a systematic review and meta-analysis.
  Lancet Psychiatry Volume: 9 Page(s): 860 - 873
  11/01/2022 Authors: Childhood Trauma Meta-Analysis Study Group
• Omega-3 Fatty Acids for Major Depressive Disorder With High Inflammation: A Randomized Dose-Finding Clinical Trial.
  J Clin Psychiatry Volume: 83
  08/22/2022 Authors: Mischoulon D; Dunlop BW; Kinkead B; Schettler PJ; Lamon-Fava S; Rakofsky JJ; Nierenberg AA; Clain AJ; Mletzko Crowe T; Wong A
• Lithium in the treatment of acute bipolar depression: A systematic review and meta-analysis.
  J Affect Disord Volume: 308 Page(s): 268 - 280
  07/01/2022 Authors: Rakofsky JJ; Lucido MJ; Dunlop BW
• Genomics-based identification of a potential causal role for acylcarnitine metabolism in depression.
  J Affect Disord Volume: 307 Page(s): 254 - 263
  06/15/2022 Authors: Milaneschi Y; Arnold M; Kastenmller G; Dehkordi SM; Krishnan RR; Dunlop BW; Rush AJ; Penninx BWJH; Kaddurah-Daouk R; Mood Disorders Precision Medicine Consortium (MDPMC)
• Metabolomic and inflammatory signatures of symptom dimensions in major depression.
  Brain Behav Immun Volume: 102 Page(s): 42 - 52
  05/01/2022 Authors: Brydges CR; Bhattacharyya S; Dehkordi SM; Milaneschi Y; Penninx B; Jansen R; Kristal BS; Han X; Arnold M; Kastenmller G
• The relations between C-reactive protein and trauma exposure, PTSD and depression symptoms, and PTSD psychotherapy treatment response in treatment seeking veterans and service members.
  Brain Behav Immun Volume: 101 Page(s): 84 - 92
  03/01/2022 Authors: Maples-Keller JL; Yasinski C; Stojek M; Ravi M; Watkins LE; Patton SC; Rothbaum AO; Unongo M; Dunlop BW; Rauch SAM
• A randomized controlled trial of 3,4-methylenedioxymethamphetamine (MDMA) and fear extinction retention in healthy adults.
  J Psychopharmacol Volume: 36 Page(s): 368 - 377
  03/01/2022 Authors: Maples-Keller JL; Norrholm SD; Burton M; Reiff C; Coghlan C; Jovanovic T; Yasinski C; Jarboe K; Rakofsky J; Rauch S
• Combinatorial pharmacogenomic algorithm is predictive of sertraline metabolism in patients with major depressive disorder.
  Psychiatry Res Volume: 308 Page(s): 114354
  02/01/2022 Authors: Parikh SV; Law RA; Hain DT; Rothschild AJ; Thase ME; Dunlop BW; DeBattista C; Forester BP; Shelton RC; Macaluso M
• The United States index of socioeconomic deprivation for individuals (USiDep).
  Pers Med Psychiatry Volume: 31-32
  01/01/2022 Authors: Dunlop BW; Rakofsky JJ; Mischoulon D; Mayberg HS; Kinkead B; Nierenberg AA; Ziegler TR; Fava M; Rapaport MH
• Gut Microbiome-Linked Metabolites in the Pathobiology of Major Depression With or Without Anxiety-A Role for Bile Acids.
  Front Neurosci Volume: 16 Page(s): 937906
  01/01/2022 Authors: MahmoudianDehkordi S; Bhattacharyya S; Brydges CR; Jia W; Fiehn O; Rush AJ; Dunlop BW; Kaddurah-Daouk R
• Making Sense of the Matrix: A Qualitative Assessment and Commentary on Connecting Psychiatric Symptom Scale Items to the Research Domain Criteria (RDoC).
  Innov Clin Neurosci Volume: 19 Page(s): 26 - 32
  01/01/2022 Authors: Citrome L; Abi-Dargham A; Bilder RM; Duffy RA; Dunlop BW; Harvey PD; Pizzagalli DA; Tamminga CA; McIntyre RS; Kane JM
• Sex Differences in Omega-3 Fatty Acids for MDD With High Inflammation
  Volume: 46 Page(s): 268 - 269
  12/01/2021 Authors: Rapaport M; Mischoulon D; Dunlop B; Nierenberg A; Kinkead B; Lamon-Fava S; Schettler P; Ziegler T; Fava M
• A Novel Peripheral Biomarker for Depression and Antidepressant Response
  Volume: 46 Page(s): 272 - 273
  12/01/2021 Authors: Targum S; Dunlop B; Schappi J; Kotsouris A; Baumik R; Rapaport M; Rasgon N; Rasenick M
• A Combinatorial Pharmacogenomic Algorithm is Predictive of Sertraline Metabolism in Patients With Major Depressive Disorder
  Volume: 46 Page(s): 273 - 274
  12/01/2021 Authors: Parikh S; Law R; Hain D; Rothschild A; Thase M; Dunlop B; DeBattista C; Forester B; Shelton R; Macaluso M
• Obesogenic Medications and Weight Gain Over 24 Weeks in Patients with Depression: Results from the GUIDED Study.
  Psychopharmacol Bull Volume: 51 Page(s): 8 - 30
  11/03/2021 Authors: Fiedorowicz JG; Brown L; Li J; Parikh SV; Dunlop BW; Forester BP; Shelton RC; Thase ME; Macaluso M; Yu K
• An intensive outpatient program with prolonged exposure for veterans with posttraumatic stress disorder: Retention, predictors, and patterns of change.
  Psychol Serv Volume: 18 Page(s): 606 - 618
  11/01/2021 Authors: Rauch SAM; Yasinski CW; Post LM; Jovanovic T; Norrholm S; Sherrill AM; Michopoulos V; Maples-Keller JL; Black K; Zwiebach L
• Indoxyl sulfate, a gut microbiome-derived uremic toxin, is associated with psychic anxiety and its functional magnetic resonance imaging-based neurologic signature.
  Sci Rep Volume: 11 Page(s): 21011
  10/25/2021 Authors: Brydges CR; Fiehn O; Mayberg HS; Schreiber H; Dehkordi SM; Bhattacharyya S; Cha J; Choi KS; Craighead WE; Krishnan RR
• Establishing Evidence for Clinical Utility of a Neuroimaging Biomarker in Major Depressive Disorder: Prospective Testing and Implementation Challenges.
  Biol Psychiatry Volume: 90 Page(s): 236 - 242
  08/15/2021 Authors: Kelley ME; Choi KS; Rajendra JK; Craighead WE; Rakofsky JJ; Dunlop BW; Mayberg HS
• Effects of Vortioxetine Versus Placebo on Cognition and Functional Capacity in Adults With Posttraumatic Stress Disorder.
  J Clin Psychopharmacol Volume: 41 Page(s): 501 - 503
  07/01/2021 Authors: Durand D; Calcagno TM; Wong A; Newport DJ; Nemeroff CB; Dunlop BW; Harvey PD
• ERICH3: vesicular association and antidepressant treatment response.
  Mol Psychiatry Volume: 26 Page(s): 2415 - 2428
  06/01/2021 Authors: Liu D; Zhuang Y; Zhang L; Gao H; Neavin D; Carrillo-Roa T; Wang Y; Yu J; Qin S; Kim DC
• Dry Those Crying Eyes: The Role of Depression and Antidepressants in Dry Eye Disease.
  J Clin Psychopharmacol Volume: 41 Page(s): 295 - 303
  05/01/2021 Authors: Rakofsky JJ; Rakofsky SI; Dunlop BW
• Safety of Using a Combinatorial Pharmacogenomic Test for Patients with Major Depressive Disorder in the GUIDED trial.
  CNS Spectr Volume: 26 Page(s): 169 - 170
  04/01/2021 Authors: Parikh SV; Khazanov GK; Thase ME; Rothschild AJ; Dunlop BW; DeBattista C; Conway CR; Forester BP; Shelton RC; Macaluso M
• Alterations in acylcarnitines, amines, and lipids inform about the mechanism of action of citalopram/escitalopram in major depression.
  Transl Psychiatry Volume: 11 Page(s): 153
  03/02/2021 Authors: MahmoudianDehkordi S; Ahmed AT; Bhattacharyya S; Han X; Baillie RA; Arnold M; Skime MK; John-Williams LS; Moseley MA; Thompson JW
• Efficacy of Vortioxetine Monotherapy for Posttraumatic Stress Disorder: A Randomized, Placebo-Controlled Trial.
  J Clin Psychopharmacol Volume: 41 Page(s): 172 - 179
  03/01/2021 Authors: Dunlop BW; Rakofsky JJ; Newport DJ; Mletzko-Crowe T; Barone K; Nemeroff CB; Harvey PD
• Combined effects of genotype and childhood adversity shape variability of DNA methylation across age.
  Transl Psychiatry Volume: 11 Page(s): 88
  02/01/2021 Authors: Czamara D; Tissink E; Tuhkanen J; Martins J; Awaloff Y; Drake AJ; Khulan B; Palotie A; Winter SM; Nemeroff CB
• Clinical validation of combinatorial pharmacogenomic testing and single-gene guidelines in predicting psychotropic medication blood levels and clinical outcomes in patients with depression.
  Psychiatry Res Volume: 296 Page(s): 113649
  02/01/2021 Authors: Rothschild AJ; Parikh SV; Hain D; Law R; Thase ME; Dunlop BW; DeBattista C; Conway CR; Forester BP; Shelton RC
• Single-cell molecular profiling of all three components of the HPA axis reveals adrenal ABCB1 as a regulator of stress adaptation.
  Sci Adv Volume: 7
  01/01/2021 Authors: Lopez JP; Brivio E; Santambrogio A; De Donno C; Kos A; Peters M; Rost N; Czamara D; Brckl TM; Roeh S
• Treatment-Specific Hippocampal Subfield Volume Changes With Antidepressant Medication or Cognitive-Behavior Therapy in Treatment-Naive Depression.
  Front Psychiatry Volume: 12 Page(s): 718539
  01/01/2021 Authors: Tai H-H; Cha J; Vedaei F; Dunlop BW; Craighead WE; Mayberg HS; Choi KS
• Moving on With Monoamine Oxidase Inhibitors.
  Focus (Am Psychiatr Publ) Volume: 19 Page(s): 50 - 52
  01/01/2021 Authors: Bodkin JA; Dunlop BW
• Navigating the Novel Psychotropics.
  Focus (Am Psychiatr Publ) Volume: 19 Page(s): 1 - 2
  01/01/2021 Authors: Dunlop BW
• Dose- and time-dependent increase in circulating anti-inflammatory and pro-resolving lipid mediators following eicosapentaenoic acid supplementation in patients with major depressive disorder and chronic inflammation.
  Prostaglandins Leukot Essent Fatty Acids Volume: 164 Page(s): 102219
  01/01/2021 Authors: Lamon-Fava S; So J; Mischoulon D; Ziegler TR; Dunlop BW; Kinkead B; Schettler PJ; Nierenberg AA; Felger JC; Maddipati KR
• Six versus twelve weeks of Swedish massage therapy for generalized anxiety disorder: Preliminary findings.
  Complement Ther Med Volume: 56 Page(s): 102593
  01/01/2021 Authors: Rapaport MH; Schettler PJ; Larson ER; Dunlop BW; Rakofsky JJ; Kinkead B
• Combinatorial Pharmacogenomic Testing Outperforms Individual Pharmacokinetic Gene Guidelines When Predicting Blood Levels of Psychotropic Medications and Clinical Outcomes in Patients With Depression
  Volume: 45 Page(s): 315 - 316
  12/01/2020 Authors: Rothschild A; Parikh S; Hain D; Law R; Thase M; Dunlop B; DeBattista C; Conway C; Forester B; Shelton R
• A Virtual Standardized Patient-Based Assessment Tool to Evaluate Psychiatric Residents' Psychopharmacology Proficiency.
  Acad Psychiatry Volume: 44 Page(s): 693 - 700
  12/01/2020 Authors: Rakofsky JJ; Talbot TB; Dunlop BW
• Combinatorial Pharmacogenomic Testing Improves Outcomes for Older Adults With Depression.
  Am J Geriatr Psychiatry Volume: 28 Page(s): 933 - 945
  09/01/2020 Authors: Forester BP; Parikh SV; Weisenbach S; Ajilore O; Vahia I; Rothschild AJ; Thase ME; Dunlop BW; DeBattista C; Conway CR
• Combinatorial Pharmacogenomic Algorithm is Predictive of Citalopram and Escitalopram Metabolism in Patients with Major Depressive Disorder.
  Psychiatry Res Volume: 290 Page(s): 113017
  08/01/2020 Authors: Shelton RC; Parikh SV; Law RA; Rothschild AJ; Thase ME; Dunlop BW; DeBattista C; Conway CR; Forester BP; Macaluso M
• Psychotherapy or medication for depression? Using individual symptom meta-analyses to derive a Symptom-Oriented Therapy (SOrT) metric for a personalised psychiatry.
  BMC Med Volume: 18 Page(s): 170
  06/05/2020 Authors: Kappelmann N; Rein M; Fietz J; Mayberg HS; Craighead WE; Dunlop BW; Nemeroff CB; Keller M; Klein DN; Arnow BA
• Longitudinal Functional Connectivity Changes With Cognitive-Behavioral Therapy or Antidepressant Medication in Major Depressive Disorder
  Volume: 87 Page(s): S303 - S303
  05/01/2020 Authors: Cha J; Choi KS; Rajendra J; Dunlop B; Craighead E; Mayberg H
• Longitudinal Hippocampal Volume Changes With Cognitive-Behavioral Therapy or Antidepressant Medication in Major Depressive Disorder
  Volume: 87 Page(s): S193 - S193
  05/01/2020 Authors: Tai H; Cha J; Dunlop B; Craighead E; Mayberg H; Choi K
• Does n-3 Fatty Acid Supplementation Impact Immune and Clinical Outcomes in Inflammatory Depression?
  Volume: 87 Page(s): S40 - S40
  05/01/2020 Authors: Rapaport M; Mischoulon D; Fava M; Dunlop B; Kinkead B; Felger J; Nierenberg A; Schettler P; Lamon-Fava S
• Beyond the bins: interpreting and discussing pharmacogenomic reports with psychiatric patients.
  Braz J Psychiatry Volume: 42 Page(s): 111 - 112
  04/01/2020 Authors: Dunlop BW
• Concordance between clinician-rated and patient reported outcome measures of depressive symptoms in treatment resistant depression.
  J Affect Disord Volume: 266 Page(s): 22 - 29
  04/01/2020 Authors: Hershenberg R; McDonald WM; Crowell A; Riva-Posse P; Craighead WE; Mayberg HS; Dunlop BW
• COMBINATORIAL PHARMACOGENETIC TESTING IMPROVES RESPONSE AND REMISSION FOR PATIENTS OVER 65 WITH DEPRESSION WHO HAVE FAILED ONE MEDICATION TRIAL
  Volume: 28 Page(s): S151 - S152
  04/01/2020 Authors: Forester BP; Parikh SV; Weisenbach S; Ajilore O; Vahia I; Rothschild AJ; Thase ME; Dunlop BW; DeBattista C; Conway CR
• 150 HAM-D6 Outcomes in a Randomized, Controlled Trial Evaluating the Utility of Combinatorial Pharmacogenomics in Depression.
  CNS Spectr Volume: 25 Page(s): 295 - 296
  04/01/2020 Authors: Dunlop BW; Parikh SV; Patel M; Rothschild AJ; Thase ME; DeBattista C; Conway CR; Forester BP; Shelton RC; Macaluso M
• Acylcarnitine metabolomic profiles inform clinically-defined major depressive phenotypes.
  J Affect Disord Volume: 264 Page(s): 90 - 97
  03/01/2020 Authors: Ahmed AT; MahmoudianDehkordi S; Bhattacharyya S; Arnold M; Liu D; Neavin D; Moseley MA; Thompson JW; Williams LSJ; Louie G
• Somatic symptoms in treatment-nave Hispanic and non-Hispanic patients with major depression.
  Depress Anxiety Volume: 37 Page(s): 156 - 165
  02/01/2020 Authors: Dunlop BW; Still S; LoParo D; Aponte-Rivera V; Johnson BN; Schneider RL; Nemeroff CB; Mayberg HS; Craighead WE
• Investigation of MORC1 DNA methylation as biomarker of early life stress and depressive symptoms.
  J Psychiatr Res Volume: 120 Page(s): 154 - 162
  01/01/2020 Authors: Thomas M; Coope A; Falkenberg C; Dunlop BW; Czamara D; Provencal N; Craighead WE; Mayberg HS; Nemeroff CB; Binder EB
• Psychophysiological treatment outcomes: Corticotropin-releasing factor type 1 receptor antagonist increases inhibition of fear-potentiated startle in PTSD patients.
  Psychophysiology Volume: 57 Page(s): e13356
  01/01/2020 Authors: Jovanovic T; Duncan EJ; Kaye J; Garza K; Norrholm SD; Inslicht SS; Neylan TC; Mathew SJ; Iosifescu D; Rothbaum BO
• Comparing sensitivity to change using the 6-item versus the 17-item Hamilton depression rating scale in the GUIDED randomized controlled trial.
  BMC Psychiatry Volume: 19 Page(s): 420
  12/27/2019 Authors: Dunlop BW; Parikh SV; Rothschild AJ; Thase ME; DeBattista C; Conway CR; Forester BP; Mondimore FM; Shelton RC; Macaluso M
• A Molecular Rationale for n-3 PUFA Augmentation of Antidepressant Action
  Volume: 44 Page(s): 434 - 434
  12/01/2019 Authors: Rapaport M; Mischoulon D; Dunlop B; Nierenberg A; Kinkead B; Lamon-Fava S; Schettler P; Ziegler T; Fava M
• Significant Weight Gain in Patients With Depression Taking Antipsychotics
  Volume: 44 Page(s): 310 - 311
  12/01/2019 Authors: Brown L; Parikh SV; Fiedorowicz JG; Thase ME; Rothschild AJ; Dunlop BW; DeBattista C; Conway CR; Forester BP; Mondimore FM
• Eicosapentaenoic Acid (EPA) Supplementation in Major Depressive Disorder Patients With Chronic Inflammation: Dose-Dependent Increases in EPA Metabolites and Specialized Pro-Resolving Lipid Mediators
  Volume: 44 Page(s): 451 - 452
  12/01/2019 Authors: Fava M; Lamon-Fava S; So J; Mischoulon D; Nierenberg A; Dunlop B; Schettler P; Kinkead B; Ziegler T; Rapaport M
• Omega-3 fatty acids for major depressive disorder with high inflammation: A personalized approach
  Volume: 29 Page(s): S250 - S251
  12/01/2019 Authors: Mischoulon D; Dunlop B; Kinkead B; Schettler P; Lamon-Fava S; Nierenberg A; Felger J; Clain A; Mletzko T; Wong A
• Changes in Dosing and Dose Timing of D-Cycloserine Explain Its Apparent Declining Efficacy for Augmenting Exposure Therapy for Anxiety-related Disorders: An Individual Participant-data Meta-analysis.
  J Anxiety Disord Volume: 68 Page(s): 102149
  12/01/2019 Authors: Rosenfield D; Smits JAJ; Hofmann SG; Mataix-Cols D; de la Cruz LF; Andersson E; Rck C; Monzani B; Prez-Vigil A; Frumento P
• Changes in trauma-potentiated startle, skin conductance, and heart rate within prolonged exposure therapy for PTSD in high and low treatment responders.
  J Anxiety Disord Volume: 68 Page(s): 102147
  12/01/2019 Authors: Maples-Keller JL; Rauch SAM; Jovanovic T; Yasinski CW; Goodnight JM; Sherrill A; Black K; Michopoulos V; Dunlop BW; Rothbaum BO
• Investigation of MORC1 DNA methylation as biomarker of early life stress and depressive symptoms
  Volume: 126 Page(s): 1543 - 1544
  11/01/2019 Authors: Thomas M; Coope A; Falkenberg C; Dunlop B; Czamara D; Provencal N; Craighead WE; Mayberg H; Nemeroff C; Binder E
• Impact of Pharmacogenomics on Clinical Outcomes for Patients Taking Medications With Gene-Drug Interactions in a Randomized Controlled Trial.
  J Clin Psychiatry Volume: 80
  10/31/2019 Authors: Thase ME; Parikh SV; Rothschild AJ; Dunlop BW; DeBattista C; Conway CR; Forester BP; Mondimore FM; Shelton RC; Macaluso M
• COMBINATORIAL PHARMACOGENOMIC TESTING IMPROVES OUTCOMES FOR PATIENTS TAKING MEDICATIONS WITH GENE-DRUG INTERACTIONS IN A RANDOMIZED, CONTROLLED TRIAL
  Volume: 29 Page(s): S132 - S133
  10/01/2019 Authors: Thase M; Parikh S; Rothschild A; Dunlop B; DeBattista C; Conway C; Forester B; Mondimore F; Shelton R; Macaluso M
• Recall accuracy for the symptoms of a major depressive episode among clinical trial participants.
  J Psychiatr Res Volume: 116 Page(s): 178 - 184
  09/01/2019 Authors: Dunlop BW; Granros M; Lechner A; Mletzko-Crowe T; Nemeroff CB; Mayberg HS; Craighead WE
• Suicidal ideation and other persisting symptoms after CBT or antidepressant medication treatment for major depressive disorder.
  Psychol Med Volume: 49 Page(s): 1869 - 1878
  08/01/2019 Authors: Dunlop BW; Polychroniou PE; Rakofsky JJ; Nemeroff CB; Craighead WE; Mayberg HS
• Metabolomic signature of exposure and response to citalopram/escitalopram in depressed outpatients.
  Transl Psychiatry Volume: 9 Page(s): 173
  07/04/2019 Authors: Bhattacharyya S; Ahmed AT; Arnold M; Liu D; Luo C; Zhu H; Mahmoudiandehkordi S; Neavin D; Louie G; Dunlop BW
• Response to: Goldberg et al. and Severance et al. Letters to the Editor: The clinical significance of improving remission over standard of care - The reality of treatment resistant-based therapies.
  J Psychiatr Res Volume: 114 Page(s): 211 - 213
  07/01/2019 Authors: Greden JF; Parikh SV; Rothschild AJ; Thase ME; Dunlop BW; DeBattista C; Conway CR; Forester BP; Mondimore FM; Shelton RC
• The symptom-specific efficacy of antidepressant medication vs. cognitive behavioral therapy in the treatment of depression: results from an individual patient data meta-analysis.
  World Psychiatry Volume: 18 Page(s): 183 - 191
  06/01/2019 Authors: Boschloo L; Bekhuis E; Weitz ES; Reijnders M; DeRubeis RJ; Dimidjian S; Dunner DL; Dunlop BW; Hegerl U; Hollon SD
• Temporal Stability of Cognitive Functioning and Functional Capacity in Women with Posttraumatic Stress Disorder.
  Arch Clin Neuropsychol Volume: 34 Page(s): 539 - 547
  06/01/2019 Authors: Gould F; Dunlop BW; Rosenthal JB; Iosifescu DV; Mathew SJ; Neylan TC; Rothbaum BO; Nemeroff CB; Harvey PD
• Short-Vs Medium plus Long-Chain Plasma Acylcarnitine in Phenotypes of Major Depression at Baseline and After Citalopram/Escitalopram Treatment
  Volume: 85 Page(s): S177 - S178
  05/15/2019 Authors: Ahmed AT; Dehkordi SM; Bhattacharyya S; Arnold M; Louie G; Dunlop B; Wang L; Weinshilboum R; Krishnan R; Bobo WV
• Moving pharmacoepigenetics tools for depression toward clinical use.
  J Affect Disord Volume: 249 Page(s): 336 - 346
  04/15/2019 Authors: Hack LM; Fries GR; Eyre HA; Bousman CA; Singh AB; Quevedo J; John VP; Baune BT; Dunlop BW
• Benefits of Sequentially Adding Cognitive-Behavioral Therapy or Antidepressant Medication for Adults With Nonremitting Depression.
  Am J Psychiatry Volume: 176 Page(s): 275 - 286
  04/01/2019 Authors: Dunlop BW; LoParo D; Kinkead B; Mletzko-Crowe T; Cole SP; Nemeroff CB; Mayberg HS; Craighead WE
• Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study.
  J Psychiatr Res Volume: 111 Page(s): 59 - 67
  04/01/2019 Authors: Greden JF; Parikh SV; Rothschild AJ; Thase ME; Dunlop BW; DeBattista C; Conway CR; Forester BP; Mondimore FM; Shelton RC
• The hypothalamic-pituitary-adrenal axis in PTSD: Pathophysiology and treatment interventions.
  Prog Neuropsychopharmacol Biol Psychiatry Volume: 89 Page(s): 361 - 379
  03/08/2019 Authors: Dunlop BW; Wong A
• SEX-SPECIFIC DIFFERENCES IN THE METABOLOME IN RESPONSE TO CITALOPRAM/ ESCITALOPRAM EXPOSURE.
  Volume: 105 Page(s): S86 - S87
  03/01/2019 Authors: Bhattacharyya S; Liu D; Ahmed AT; Mahmoudiandehkordi S; Arnold M; Luo C; Zhu H; Neavin D; Athreya AP; Louie G
• METABOLOMIC SIGNATURE OF EXPOSURE AND RESPONSE TO CITALOPRAM/ESCITALOPRAM IN CLINICAL SUBTYPES OF MAJOR DEPRESSION: METABOLOMICS INFORMS ABOUT DISEASE HETEROGENEITY.
  Volume: 105 Page(s): S50 - S50
  03/01/2019 Authors: Ahmed A; Bhattacharyya S; Mahmoudiandehkordi S; Liu D; Arnold M; Neavin D; Athreya A; Louie G; Dunlop B; Wang L
• SEX-SPECIFIC DIFFERENCES IN THE METABOLOME IN RESPONSE TO CITALOPRAM/ESCITALOPRAM EXPOSURE.
  Volume: 105 Page(s): S9 - S9
  03/01/2019 Authors: Bhattacharyya S; Liu D; Ahmed AT; Mahmoudiandehkordi S; Arnold M; Luo C; Zhu H; Neavin D; Athreya AP; Louie G
• METABOLOMIC SIGNATURES OF DRUG RESPONSE PHENOTYPES FOR CITALOPRAM AND ESCITALOPRAM IN SUBJECTS WITH MAJOR DEPRESSIVE DISORDER.
  Volume: 105 Page(s): S10 - S10
  03/01/2019 Authors: Mahmoudiandehkordi S; Bhattacharyya S; Liu D; Ahmed A; Arnold M; Luo C; Zhu H; Neavin D; Athreya A; Louie G
• METABOLOMIC SIGNATURES OF DRUG RESPONSE PHENOTYPES FOR CITALOPRAM AND ESCITALOPRAM IN SUBJECTS WITH MAJOR DEPRESSIVE DISORDER.
  Volume: 105 Page(s): S105 - S105
  03/01/2019 Authors: Mahmoudiandehkordi S; Bhattacharyya S; Liu D; Ahmed A; Arnold M; Luo C; Zhu H; Neavin D; Athreya A; Louie G
• METABOLOMIC SIGNATURE OF EXPOSURE AND RESPONSE TO CITALOPRAM/ESCITALOPRAM IN CLINICAL SUBTYPES OF MAJOR DEPRESSION: METABOLOMICS INFORMS ABOUT DISEASE HETEROGENEITY.
  Volume: 105 Page(s): S9 - S10
  03/01/2019 Authors: Ahmed A; Bhattacharyya S; Mahmoudiandehkordi S; Liu D; Arnold M; Neavin D; Athreya A; Louie G; Dunlop B; Wang L
• 49 Combinatorial Pharmacogenomics to Guide Treatment Selection for Major Depressive Disorder: A Large, Blinded, Randomized Controlled Trial.
  CNS Spectr Volume: 24 Page(s): 202 - 203
  02/01/2019 Authors: Greden JF; Rosthschild AJ; Thase M; Dunlop BW; DeBattista DC; Conway CR; Forester BP; Mondimore FM; Shelton RC; Li J
• When translational neuroscience fails in the clinic: Dexamethasone prior to virtual reality exposure therapy increases drop-out rates.
  J Anxiety Disord Volume: 61 Page(s): 89 - 97
  01/01/2019 Authors: Maples-Keller JL; Jovanovic T; Dunlop BW; Rauch S; Yasinski C; Michopoulos V; Coghlan C; Norrholm S; Rizzo AS; Ressler K
• Pharmacogenetic tests and depressive symptom remission: a meta-analysis of randomized controlled trials.
  Pharmacogenomics Volume: 20 Page(s): 37 - 47
  01/01/2019 Authors: Bousman CA; Arandjelovic K; Mancuso SG; Eyre HA; Dunlop BW
• Pilot Study of Metabolomic Clusters as State Markers of Major Depression and Outcomes to CBT Treatment.
  Front Neurosci Volume: 13 Page(s): 926
  01/01/2019 Authors: Bhattacharyya S; Dunlop BW; Mahmoudiandehkordi S; Ahmed AT; Louie G; Frye MA; Weinshilboum RM; Krishnan RR; Rush AJ; Mayberg HS
• Combinatorial Pharmacogenetic Testing-Informed Medication Switching From Genetically Incongruent to Congruent Medications Leads to Decreased Side Effect-Burden for Patients With Depression
  Volume: 43 Page(s): S124 - S124
  12/01/2018 Authors: Greden J; Parikh S; Rothschild A; Thase M; Dunlop B; DeBattista C; Conway C; Forester B; Mondimore F; Shelton R
• Trauma Potentiated Startle and Cortisol Reactivity as Psychophysiological Mechanisms of Treatment Response Within Prolonged Exposure Therapy for Post-traumatic Stress Disorder
  Volume: 43 Page(s): S467 - S468
  12/01/2018 Authors: Maples-Keller J; Norrholm S; Jovanovic T; Yasinski C; Goodnight J; Sherrill A; Black K; Michopoulos V; Dunlop B; Rothbaum B
• DNA methylation levels are associated with CRF1 receptor antagonist treatment outcome in women with post-traumatic stress disorder.
  Clin Epigenetics Volume: 10 Page(s): 136
  11/03/2018 Authors: Pape JC; Carrillo-Roa T; Rothbaum BO; Nemeroff CB; Czamara D; Zannas AS; Iosifescu D; Mathew SJ; Neylan TC; Mayberg HS
• Model structure for protocol adherence utilizing a manualized therapeutic massage intervention.
  J Complement Integr Med Volume: 16
  10/12/2018 Authors: Larson ER; Kinkead B; Edwards SA; Schettler PJ; Dunlop BW; Rakofsky JJ; Rapaport MH
• Response rate profiles for major depressive disorder: Characterizing early response and longitudinal nonresponse.
  Depress Anxiety Volume: 35 Page(s): 992 - 1000
  10/01/2018 Authors: Kelley ME; Dunlop BW; Nemeroff CB; Lori A; Carrillo-Roa T; Binder EB; Kutner MH; Rivera VA; Craighead WE; Mayberg HS
• Mapping depression rating scale phenotypes onto research domain criteria (RDoC) to inform biological research in mood disorders.
  J Affect Disord Volume: 238 Page(s): 1 - 7
  10/01/2018 Authors: Ahmed AT; Frye MA; Rush AJ; Biernacka JM; Craighead WE; McDonald WM; Bobo WV; Riva-Posse P; Tye SJ; Mayberg HS
• Imaging the Future of Major Depression.
  Focus (Am Psychiatr Publ) Volume: 16 Page(s): 3s
  10/01/2018 Authors: Dunlop BW
• Defective Inflammatory Pathways in Never-Treated Depressed Patients Are Associated with Poor Treatment Response.
  Neuron Volume: 99 Page(s): 914 - 924.e3
  09/05/2018 Authors: Syed SA; Beurel E; Loewenstein DA; Lowell JA; Craighead WE; Dunlop BW; Mayberg HS; Dhabhar F; Dietrich WD; Keane RW
• Genotype, phenotype, and medication recommendation agreement among commercial pharmacogenetic-based decision support tools.
  Pharmacogenomics J Volume: 18 Page(s): 613 - 622
  09/01/2018 Authors: Bousman CA; Dunlop BW
• Blood pressure safety of subanesthetic ketamine for depression: A report on 684 infusions.
  J Affect Disord Volume: 236 Page(s): 291 - 297
  08/15/2018 Authors: Riva-Posse P; Reiff CM; Edwards JA; Job GP; Galendez GC; Garlow SJ; Saah TC; Dunlop BW; McDonald WM
• Temporal Profiles and Dose-Responsiveness of Side Effects with Escitalopram and Duloxetine in Treatment-Nave Depressed Adults.
  Behav Sci (Basel) Volume: 8
  07/17/2018 Authors: Polychroniou PE; Mayberg HS; Craighead WE; Rakofsky JJ; Aponte Rivera V; Haroon E; Dunlop BW
• More Research Needed on the Association Between Genotype and Antidepressant Response: Response to Fabbri et al (vol 175, pg 576, 2018)
  AMERICAN JOURNAL OF PSYCHIATRY Volume: 175 Page(s): 685 - 685
  07/01/2018 Authors: O'Connell CP; Goldstein-Piekarski AN; Nemeroff CB; Schatzberg AF; Debattista C; Carrillo-Roa T; Binder EB; Dunlop BW; Craighead WE; Mayberg HS
• Would Addressing Alcohol Consumption Further Account for Variance in Methylation?
  Am J Psychiatry Volume: 175 Page(s): 684 - 685
  07/01/2018 Authors: Philibert RA; Beach SRH
• Placebo Effects Across Self-Report, Clinician Rating, and Objective Performance Tasks Among Women With Post-Traumatic Stress Disorder: Investigation of Placebo Response in a Pharmacological Treatment Study of Post-Traumatic Stress Disorder.
  J Clin Psychopharmacol Volume: 38 Page(s): 200 - 206
  06/01/2018 Authors: Hodgins GE; Blommel JG; Dunlop BW; Iosifescu D; Mathew SJ; Neylan TC; Mayberg HS; Harvey PD
• Epigenetic Biomarkers in Women With Posttraumatic Stress Disorder After CRF1 Receptor Antagonist Treatment
  Volume: 83 Page(s): S308 - S308
  05/01/2018 Authors: Pape J; Carrillo-Roa T; Wiechmann T; Roeh S; Rothbaum B; Nemeroff C; Czamara D; Zannas A; Iosifescu D; Mathew S
• Performance of the Adult ADHD Self-Report Scale-v1.1 in Adults with Major Depressive Disorder.
  Behav Sci (Basel) Volume: 8
  03/29/2018 Authors: Dunlop BW; Wu R; Helms K
• Differential change on depressive symptom factors with antidepressant medication and cognitive behavior therapy for major depressive disorder.
  J Affect Disord Volume: 229 Page(s): 111 - 119
  03/15/2018 Authors: Dunlop BW; Cole SP; Nemeroff CB; Mayberg HS; Craighead WE
• Antidepressant Outcomes Predicted by Genetic Variation in Corticotropin-Releasing Hormone Binding Protein.
  Am J Psychiatry Volume: 175 Page(s): 251 - 261
  03/01/2018 Authors: O'Connell CP; Goldstein-Piekarski AN; Nemeroff CB; Schatzberg AF; Debattista C; Carrillo-Roa T; Binder EB; Dunlop BW; Craighead WE; Mayberg HS
• Follow-up of monotherapy remitters in the PReDICT study: Maintenance treatment outcomes and clinical predictors of recurrence.
  J Consult Clin Psychol Volume: 86 Page(s): 189 - 199
  02/01/2018 Authors: Kennedy JC; Dunlop BW; Craighead LW; Nemeroff CB; Mayberg HS; Craighead WE
• Massage therapy decreases cancer-related fatigue: Results from a randomized early phase trial.
  Cancer Volume: 124 Page(s): 546 - 554
  02/01/2018 Authors: Kinkead B; Schettler PJ; Larson ER; Carroll D; Sharenko M; Nettles J; Edwards SA; Miller AH; Torres MA; Dunlop BW
• Test-Retest Reliability of the SERT Imaging Agent 11C-HOMADAM in Healthy Humans.
  J Nucl Med Volume: 59 Page(s): 315 - 319
  02/01/2018 Authors: Adhikarla V; Dunlop BW; Jarkas N; Goodman MM; Mayberg H; Owens MJ; Nye JA
• Double-blind, proof-of-concept (POC) trial of Low-Field Magnetic Stimulation (LFMS) augmentation of antidepressant therapy in treatment-resistant depression (TRD).
  Brain Stimul Volume: 11 Page(s): 75 - 84
  01/01/2018 Authors: Fava M; Freeman MP; Flynn M; Hoeppner BB; Shelton R; Iosifescu DV; Murrough JW; Mischoulon D; Cusin C; Rapaport M
• Corticotropin-Releasing Factor Receptor 1 Antagonism Is Ineffective for Women With Posttraumatic Stress Disorder.
  Biol Psychiatry Volume: 82 Page(s): 866 - 874
  12/15/2017 Authors: Dunlop BW; Binder EB; Iosifescu D; Mathew SJ; Neylan TC; Pape JC; Carrillo-Roa T; Green C; Kinkead B; Grigoriadis D
• Hyper-responsivity to losses in the anterior insula during economic choice scales with depression severity.
  Psychol Med Volume: 47 Page(s): 2879 - 2891
  12/01/2017 Authors: Engelmann JB; Berns GS; Dunlop BW
• Common genes associated with antidepressant response in mouse and man identify key role of glucocorticoid receptor sensitivity.
  PLoS Biol Volume: 15 Page(s): e2002690
  12/01/2017 Authors: Carrillo-Roa T; Labermaier C; Weber P; Herzog DP; Lareau C; Santarelli S; Wagner KV; Rex-Haffner M; Harbich D; Scharf SH
• Do Commercial Pharmacogenetic-Based Decision Support Tools Provide Concordant Medication Recommendations?
  Volume: 42 Page(s): S555 - S556
  11/01/2017 Authors: Bousman C; Dunlop B
• Reported maladaptive decision-making in unipolar and bipolar depression and its change with treatment.
  Psychiatry Res Volume: 257 Page(s): 386 - 392
  11/01/2017 Authors: Alexander LF; Oliver A; Burdine LK; Tang Y; Dunlop BW
• Pharmacogenetic Decision Support Tools: A Component of Precision Medicine for Psychiatry?
  Focus (Am Psychiatr Publ) Volume: 15 Page(s): 3s - 4s
  10/01/2017 Authors: Dunlop BW
• Surveying Psychiatrists' Psychopharmacology Practices Across Common Clinical Scenarios.
  Focus (Am Psychiatr Publ) Volume: 15 Page(s): 445 - 449
  10/01/2017 Authors: Dunlop BW; Rakofsky JJ
• Inhibition of serotonin transporters disrupts the enhancement of fear memory extinction by 3,4-methylenedioxymethamphetamine (MDMA).
  Psychopharmacology (Berl) Volume: 234 Page(s): 2883 - 2895
  10/01/2017 Authors: Young MB; Norrholm SD; Khoury LM; Jovanovic T; Rauch SAM; Reiff CM; Dunlop BW; Rothbaum BO; Howell LL
• 2018 American Society of Consultant Pharmacists Annual Meeting & Exhibition.
  Consult Pharm Volume: 33 Page(s): 572 - 608
  10/01/2017 Authors: Bridgeman M; Prete D; Rolston N; Abazia D; Sturgill M; Finn L; Summers D; Marvanova M; Henkel P; Thompson J
• How Shall I Diagnose Thee? Let Me Count the Ways.
  Biol Psychiatry Volume: 82 Page(s): 306 - 308
  09/01/2017 Authors: Dunlop BW
• Transdiagnostic Clinical Global Impression Scoring for Routine Clinical Settings.
  Behav Sci (Basel) Volume: 7
  06/27/2017 Authors: Dunlop BW; Gray J; Rapaport MH
• Functional Connectivity of the Subcallosal Cingulate Cortex And Differential Outcomes to Treatment With Cognitive-Behavioral Therapy or Antidepressant Medication for Major Depressive Disorder.
  Am J Psychiatry Volume: 174 Page(s): 533 - 545
  06/01/2017 Authors: Dunlop BW; Rajendra JK; Craighead WE; Kelley ME; McGrath CL; Choi KS; Kinkead B; Nemeroff CB; Mayberg HS
• Effects of Patient Preferences on Outcomes in the Predictors of Remission in Depression to Individual and Combined Treatments (PReDICT) Study.
  Am J Psychiatry Volume: 174 Page(s): 546 - 556
  06/01/2017 Authors: Dunlop BW; Kelley ME; Aponte-Rivera V; Mletzko-Crowe T; Kinkead B; Ritchie JC; Nemeroff CB; Craighead WE; Mayberg HS; PReDICT Team
• Assessing Residents' Confidence in the Context of Pharmacotherapy Competence.
  Acad Psychiatry Volume: 41 Page(s): 350 - 353
  06/01/2017 Authors: Rakofsky JJ; Garlow SJ; Haroon E; Hermida AP; Young JQ; Dunlop BW
• Functional Connectivity of the Subcallosal Cingulate Cortex and Differential Outcomes to Treatment With Cognitive-Behavioral Therapy or Antidepressant Medication for Major Depressive Disorder (vol 174, pg 533, 2017)
  AMERICAN JOURNAL OF PSYCHIATRY Volume: 174 Page(s): 604 - 604
  06/01/2017 Authors: Dunlop BW
• Clinical Staging of Major Depression: Multimodal-Imaging Approach
  Volume: 81 Page(s): S241 - S242
  05/15/2017 Authors: Choi KS; Rajendra J; Dunlop B; Mayberg H
• DNA Methylation Biomarkers and Treatment Effects of a Corticotropin Releasing Hormone Type 1 Receptor Antagonist in a Biologically-Defined Subset of PTSD-Patients
  Volume: 81 Page(s): S222 - S222
  05/15/2017 Authors: Pape J; Carrillo-Roa T; Iosifescu D; Mathew S; Neylan T; Nemeroff C; Mayberg H; Dunlop B; Binder E
• The CRH-1 Receptor Antagonist Saga in Mood and Anxiety Disorders: The Good, the Bad and the Ugly
  Volume: 81 Page(s): S279 - S279
  05/15/2017 Authors: Nemeroff C; Dunlop B
• The Temporal Stability of Cognitive Functioning and Functional Capacity in Women with PTSD
  Volume: 81 Page(s): S213 - S213
  05/15/2017 Authors: Gould F; Dunlop B; Rosenthal J; Iosifescu D; Mathew S; Neylan T; Rothbaum B; Nemeroff C; Harvey P
• D-Cycloserine Augmentation of Exposure-Based Cognitive Behavior Therapy for Anxiety, Obsessive-Compulsive, and Posttraumatic Stress Disorders: A Systematic Review and Meta-analysis of Individual Participant Data.
  JAMA Psychiatry Volume: 74 Page(s): 501 - 510
  05/01/2017 Authors: Mataix-Cols D; Fernndez de la Cruz L; Monzani B; Rosenfield D; Andersson E; Prez-Vigil A; Frumento P; de Kleine RA; Difede J; Dunlop BW
• Melancholic and atypical depression as predictor and moderator of outcome in cognitive behavior therapy and pharmacotherapy for adult depression.
  Depress Anxiety Volume: 34 Page(s): 246 - 256
  03/01/2017 Authors: Cuijpers P; Weitz E; Lamers F; Penninx BW; Twisk J; DeRubeis RJ; Dimidjian S; Dunlop BW; Jarrett RB; Segal ZV
• SUBPHENOTYPES IN MAJOR DEPRESSIVE DISORDER TO BETTER CHARACTERIZE PHARMACOGENOMIC ANTIDEPRESSANT TREATMENT RESPONSE
  Volume: 101 Page(s): S19 - S20
  02/01/2017 Authors: Ahmed AT; Frye MA; Rush A; Bobo WV; Biernacka J; Flavin DH; Jenkins GD; Batzle A; Skime MK; Wang L
• The Structure of Personality Disorders within a Depressed Sample: Implications for Personalizing Treatment.
  Pers Med Psychiatry Volume: 1-2 Page(s): 59 - 64
  01/01/2017 Authors: Berg JM; Kennedy JC; Dunlop BW; Ramirez CL; Stewart LM; Nemeroff CB; Mayberg HS; Craighead WE
• Neuroimaging Advances for Depression.
  Cerebrum Volume: 2017
  01/01/2017 Authors: Dunlop BW; Mayberg HS
• Placebo Effects in a PTSD Trial of a CRH Antagonist: Not Limited to Clinical Measures
  Volume: 41 Page(s): S331 - S332
  12/01/2016 Authors: Hodgins G; Blommel J; Dunlop B; Iosifescu D; Mathew S; Neylan T; Nemeroff C; Harvey P
• Swedish Massage Therapy Clinically and Statistically Reduced Fatigue in Breast Cancer Survivors
  Volume: 41 Page(s): S381 - S381
  12/01/2016 Authors: Rapaport M; Dunlop B; Kinkead B; Rakofsky J; Schettler P; Edwards S; Torres M; Larsen E; Allen L; Carroll D
• When Should a Patient Be Declared Recovered From a Major Depressive Episode?
  J Clin Psychiatry Volume: 77 Page(s): e1026 - e1028
  08/01/2016 Authors: Dunlop BW; Rapaport MH
• Acute Swedish Massage Monotherapy Successfully Remediates Symptoms of Generalized Anxiety Disorder: A Proof-of-Concept, Randomized Controlled Study.
  J Clin Psychiatry Volume: 77 Page(s): e883 - e891
  07/01/2016 Authors: Rapaport MH; Schettler P; Larson ER; Edwards SA; Dunlop BW; Rakofsky JJ; Kinkead B
• Time-dependent effects of dexamethasone plasma concentrations on glucocorticoid receptor challenge tests.
  Psychoneuroendocrinology Volume: 69 Page(s): 161 - 171
  07/01/2016 Authors: Menke A; Arloth J; Best J; Namendorf C; Gerlach T; Czamara D; Lucae S; Dunlop BW; Crowe TM; Garlow SJ
• Analysis of Rare Variants in ADRA1a with Response to Treatment for Major Depressive Disorder (MDD)
  Volume: 79 Page(s): 225S - 226S
  05/01/2016 Authors: Lori A; Carillo-Roa T; Binder EB; Mayberg HS; McGrath CL; Mletzko T; Laird JL; Czamara D; Dunlop BW; Craighead WE
• Polygenic Scores Derived from Neuroimaging Endophenotypes Predict Outcomes to Psychotherapy and Medication Treatments for Major Depressive Disorder
  Volume: 79 Page(s): 155S - 156S
  05/01/2016 Authors: Carrillo-Roa T; Dunlop BW; McGrath CL; Czamara D; Zannas AS; Kelley ME; Nemeroff CB; Mueller-Myhsok B; Craighead WE; Mayberg HS
• Divergent Outcomes in Cognitive-Behavioral Therapy and Pharmacotherapy for Adult Depression.
  Am J Psychiatry Volume: 173 Page(s): 481 - 490
  05/01/2016 Authors: Vittengl JR; Jarrett RB; Weitz E; Hollon SD; Twisk J; Cristea I; David D; DeRubeis RJ; Dimidjian S; Dunlop BW
• Evidence-Based Applications of Combination Psychotherapy and Pharmacotherapy for Depression.
  Focus (Am Psychiatr Publ) Volume: 14 Page(s): 156 - 173
  04/01/2016 Authors: Dunlop BW
• Neuroimaging derived polygenic scores predict outcomes to psychotherapy and medication treatments for depression
  Volume: 26 Page(s): S48 - S49
  03/01/2016 Authors: Carrillo-Roa T; Dunlop BW; McGrath CL; Czamara D; Zaanas AS; Kelley ME; Nemeroff CB; Craighead WE; Mayberg HS; Binder EB
• Depression Worsening Associated With Lorcaserin: A Case Report.
  J Clin Psychopharmacol Volume: 35 Page(s): 747 - 748
  12/01/2015 Authors: Rakofsky JJ; Tang Y; Dunlop BW
• Baseline Depression Severity as Moderator of Depression Outcomes Between Cognitive Behavioral Therapy vs Pharmacotherapy: An Individual Patient Data Meta-analysis.
  JAMA Psychiatry Volume: 72 Page(s): 1102 - 1109
  11/01/2015 Authors: Weitz ES; Hollon SD; Twisk J; van Straten A; Huibers MJH; David D; DeRubeis RJ; Dimidjian S; Dunlop BW; Cristea IA
• Prediction of treatment outcomes in major depressive disorder.
  Expert Rev Clin Pharmacol Volume: 8 Page(s): 669 - 672
  11/01/2015 Authors: Dunlop BW
• Assessment of the Efficacy and Safety of BMS-820836 in Patients With Treatment-Resistant Major Depression: Results From 2 Randomized, Double-Blind Studies.
  J Clin Psychopharmacol Volume: 35 Page(s): 454 - 459
  08/01/2015 Authors: Bhagwagar Z; Torbeyns A; Hennicken D; Zheng M; Dunlop BW; Mathew SJ; Khan A; Weisler R; Nelson C; Shelton R
• Antidepressant signal detection in the clinical trials vortex.
  J Clin Psychiatry Volume: 76 Page(s): e657 - e659
  05/01/2015 Authors: Dunlop BW; Rapaport MH
• Polygenic Predictors of Antidepressant Treatment-Specific Response
  Volume: 77
  05/01/2015 Authors: Carrillo-Roa T; McGrath CL; Zannas AS; Muller-Myhsok B; Kelley ME; Craighead WE; Dunlop BW; Mayberg HS; Binder EB
• Association of Rare Variants in ADRA1a with Response to Treatment for Major Depressive Disorder (MDD)
  Volume: 77
  05/01/2015 Authors: Lori A; Tania C-R; Binder EB; Mayberg HS; McGrath CL; Mletzko TC; Dunlop BW; Craighead EW; Kelley ME; Mulle JG
• Mediators of sexual functioning and marital quality in chronically depressed adults with and without a history of childhood sexual abuse.
  J Sex Med Volume: 12 Page(s): 813 - 823
  03/01/2015 Authors: Dunlop BW; Hill E; Johnson BN; Klein DN; Gelenberg AJ; Rothbaum BO; Thase ME; Kocsis JH
• Prediction of treatment outcomes in major depressive disorder.
  Expert Rev Clin Pharmacol Volume: 8 Page(s): 669 - 672
  01/01/2015 Authors: Dunlop BW
• Preliminary Findings Supporting Insula Metabolic Activity as a Predictor of Outcome to Psychotherapy and Medication Treatments for Depression.
  J Neuropsychiatry Clin Neurosci Volume: 27 Page(s): 237 - 239
  01/01/2015 Authors: Dunlop BW; Kelley ME; McGrath CL; Craighead WE; Mayberg HS
• Assessing Treatment-Resistant Posttraumatic Stress Disorder: The Emory Treatment Resistance Interview for PTSD (E-TRIP).
  Behav Sci (Basel) Volume: 4 Page(s): 511 - 527
  12/08/2014 Authors: Dunlop BW; Kaye JL; Youngner C; Rothbaum B
• Neuroimaging-based biomarkers for treatment selection in major depressive disorder.
  Dialogues Clin Neurosci Volume: 16 Page(s): 479 - 490
  12/01/2014 Authors: Dunlop BW; Mayberg HS
• Estimates of Serotonin or Norepinephrine Transporter Occupancy Do Not Predict Antidepressant Response in a 12 Week Trial
  Volume: 39 Page(s): S460 - S461
  12/01/2014 Authors: Owens M; Dunlop B; Plott S; Zejnelovic F; Craighead WE; Mayberg H; Nemeroff C
• Gender as predictor and moderator of outcome in cognitive behavior therapy and pharmacotherapy for adult depression: an "individual patient data" meta-analysis.
  Depress Anxiety Volume: 31 Page(s): 941 - 951
  11/01/2014 Authors: Cuijpers P; Weitz E; Twisk J; Kuehner C; Cristea I; David D; DeRubeis RJ; Dimidjian S; Dunlop BW; Faramarzi M
• How well do clinicians and patients agree on depression treatment outcomes? Implications for personalized medicine.
  Hum Psychopharmacol Volume: 29 Page(s): 528 - 536
  11/01/2014 Authors: Dunlop BW; McCabe B; Eudicone JM; Sheehan JJ; Baker RA
• Ziprasidone monotherapy is ineffective for bipolar-associated anxiety.
  Evid Based Ment Health Volume: 17 Page(s): 109
  11/01/2014 Authors: Dunlop BW
• Cognition, functional capacity, and self-reported disability in women with posttraumatic stress disorder: examining the convergence of performance-based measures and self-reports.
  J Psychiatr Res Volume: 57 Page(s): 51 - 57
  10/01/2014 Authors: Kaye JL; Dunlop BW; Iosifescu DV; Mathew SJ; Kelley ME; Harvey PD
• Pretreatment brain states identify likely nonresponse to standard treatments for depression.
  Biol Psychiatry Volume: 76 Page(s): 527 - 535
  10/01/2014 Authors: McGrath CL; Kelley ME; Dunlop BW; Holtzheimer PE; Craighead WE; Mayberg HS
• MicroRNA 135 is essential for chronic stress resiliency, antidepressant efficacy, and intact serotonergic activity.
  Neuron Volume: 83 Page(s): 344 - 360
  07/16/2014 Authors: Issler O; Haramati S; Paul ED; Maeno H; Navon I; Zwang R; Gil S; Mayberg HS; Dunlop BW; Menke A
• Evaluation of a corticotropin releasing hormone type 1 receptor antagonist in women with posttraumatic stress disorder: study protocol for a randomized controlled trial.
  Trials Volume: 15 Page(s): 240
  06/21/2014 Authors: Dunlop BW; Rothbaum BO; Binder EB; Duncan E; Harvey PD; Jovanovic T; Kelley ME; Kinkead B; Kutner M; Iosifescu DV
• Cognitive effects of quetiapine XR in patients with euthymic bipolar disorder.
  J Clin Psychopharmacol Volume: 34 Page(s): 383 - 385
  06/01/2014 Authors: Rakofsky JJ; Dunlop BW; Beyer JL; Oliver AM; Mansson EE; Sancheti MT; Harvey PD
• A randomized, double-blind evaluation of D-cycloserine or alprazolam combined with virtual reality exposure therapy for posttraumatic stress disorder in Iraq and Afghanistan War veterans.
  Am J Psychiatry Volume: 171 Page(s): 640 - 648
  06/01/2014 Authors: Rothbaum BO; Price M; Jovanovic T; Norrholm SD; Gerardi M; Dunlop B; Davis M; Bradley B; Duncan EJ; Rizzo A
• Review of nutritional supplements for the treatment of bipolar depression.
  Depress Anxiety Volume: 31 Page(s): 379 - 390
  05/01/2014 Authors: Rakofsky JJ; Dunlop BW
• Reconciling variable findings of white matter integrity in major depressive disorder.
  Neuropsychopharmacology Volume: 39 Page(s): 1332 - 1339
  05/01/2014 Authors: Choi KS; Holtzheimer PE; Franco AR; Kelley ME; Dunlop BW; Hu XP; Mayberg HS
• Enhancing Hispanic participation in mental health clinical research: development of a Spanish-speaking depression research site.
  Depress Anxiety Volume: 31 Page(s): 258 - 267
  03/01/2014 Authors: Aponte-Rivera V; Dunlop BW; Ramirez C; Kelley ME; Schneider R; Blastos B; Larson J; Mercado F; Mayberg H; Craighead WE
• Combination psychotherapy and antidepressant medication treatment for depression: for whom, when, and how.
  Annu Rev Psychol Volume: 65 Page(s): 267 - 300
  01/01/2014 Authors: Craighead WE; Dunlop BW
• Posttraumatic stress disorder increases sensitivity to long term losses among patients with major depressive disorder.
  PLoS One Volume: 9 Page(s): e95819
  01/01/2014 Authors: Engelmann JB; Maciuba B; Vaughan C; Paulus MP; Dunlop BW
• Efficacy and safety of desvenlafaxine 50 mg/d in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder.
  J Clin Psychiatry Volume: 74 Page(s): 1010 - 1017
  10/01/2013 Authors: Clayton AH; Kornstein SG; Dunlop BW; Focht K; Musgnung J; Ramey T; Bao W; Ninan PT
• Ten ways to improve the treatment of depression and anxiety in adults.
  Ment Health Fam Med Volume: 10 Page(s): 175 - 181
  09/01/2013 Authors: Dunlop BW; Scheinberg K; Dunlop AL
• Toward a neuroimaging treatment selection biomarker for major depressive disorder.
  JAMA Psychiatry Volume: 70 Page(s): 821 - 829
  08/01/2013 Authors: McGrath CL; Kelley ME; Holtzheimer PE; Dunlop BW; Craighead WE; Franco AR; Craddock RC; Mayberg HS
• Cognitive effects of quetiapine XR in patients with euthymic bipolar disorder
  Volume: 15 Page(s): 75 - 75
  06/01/2013 Authors: Rakofsky JJ; Dunlop BW; Beyer JL; Oliver AM; Mansson EE; Sancheti MT; Harvey PD
• Do alcohol use disorders destabilize the course of bipolar disorder?
  J Affect Disord Volume: 145 Page(s): 1 - 10
  02/15/2013 Authors: Rakofsky JJ; Dunlop BW
• Posttraumatic stress disorder increases sensitivity to long term losses among patients with major depressive disorder.
  PLoS One Volume: 8 Page(s): e78292
  01/01/2013 Authors: Engelmann JB; Maciuba B; Vaughan C; Paulus MP; Dunlop BW
• A simple question answered: adding moderate-dosage lithium does not help patients with bipolar disorder.
  Am J Psychiatry Volume: 170 Page(s): 9 - 11
  01/01/2013 Authors: Dunlop BW; Rakofsky JJ; Rapaport MH
• A meta-analysis of factors impacting detection of antidepressant efficacy in clinical trials: the importance of academic sites.
  Neuropsychopharmacology Volume: 37 Page(s): 2830 - 2836
  12/01/2012 Authors: Dunlop BW; Thase ME; Wun C-C; Fayyad R; Guico-Pabia CJ; Musgnung J; Ninan PT
• The combination of triiodothyronine (T3) and sertraline is not superior to sertraline monotherapy in the treatment of major depressive disorder.
  J Psychiatr Res Volume: 46 Page(s): 1406 - 1413
  11/01/2012 Authors: Garlow SJ; Dunlop BW; Ninan PT; Nemeroff CB
• Predictors of remission in depression to individual and combined treatments (PReDICT): study protocol for a randomized controlled trial.
  Trials Volume: 13 Page(s): 106
  07/09/2012 Authors: Dunlop BW; Binder EB; Cubells JF; Goodman MM; Kelley ME; Kinkead B; Kutner M; Nemeroff CB; Newport DJ; Owens MJ
• Recovery and subsequent recurrence in patients with recurrent major depressive disorder.
  J Psychiatr Res Volume: 46 Page(s): 708 - 715
  06/01/2012 Authors: Dunlop BW; Holland P; Bao W; Ninan PT; Keller MB
• US psychiatric residents' treatment of patients with bipolar disorder.
  J Clin Psychopharmacol Volume: 32 Page(s): 231 - 236
  04/01/2012 Authors: Rakofsky JJ; Dunlop BW
• Depression beliefs, treatment preference, and outcomes in a randomized trial for major depressive disorder.
  J Psychiatr Res Volume: 46 Page(s): 375 - 381
  03/01/2012 Authors: Dunlop BW; Kelley ME; Mletzko TC; Velasquez CM; Craighead WE; Mayberg HS
• Pharmacology and neuroimaging of antidepressant action.
  Handb Clin Neurol Volume: 106 Page(s): 643 - 655
  01/01/2012 Authors: Dunlop BW; Lecrubier Y; Fossati P
• Pharmacological innovations for posttraumatic stress disorder and medication- enhanced psychotherapy.
  Curr Pharm Des Volume: 18 Page(s): 5645 - 5658
  01/01/2012 Authors: Dunlop BW; Mansson E; Gerardi M
• BDNF function as a potential mediator of bipolar disorder and post-traumatic stress disorder comorbidity.
  Mol Psychiatry Volume: 17 Page(s): 22 - 35
  01/01/2012 Authors: Rakofsky JJ; Ressler KJ; Dunlop BW
• Public health consequences of state immigration laws.
  South Med J Volume: 104 Page(s): 718 - 719
  11/01/2011 Authors: Aponte-Rivera VR; Dunlop BW
• The effects of sertraline on psychopathic traits.
  Int Clin Psychopharmacol Volume: 26 Page(s): 329 - 337
  11/01/2011 Authors: Dunlop BW; DeFife JA; Marx L; Garlow SJ; Nemeroff CB; Lilienfeld SO
• Symptomatic and functional improvement in employed depressed patients: a double-blind clinical trial of desvenlafaxine versus placebo.
  J Clin Psychopharmacol Volume: 31 Page(s): 569 - 576
  10/01/2011 Authors: Dunlop BW; Reddy S; Yang L; Lubaczewski S; Focht K; Guico-Pabia CJ
• Preconsent education about research processes improved African Americans' willingness to participate in clinical research.
  J Clin Epidemiol Volume: 64 Page(s): 872 - 877
  08/01/2011 Authors: Dunlop AL; Leroy ZC; Logue KM; Glanz K; Dunlop BW
• Pretreatment Resting State FDG-PET Predicts Differential Response to CBT or Medication
  Volume: 69 Page(s): 168S - 168S
  05/01/2011 Authors: McGrath CL; Holtzheimer PE; Kelley ME; Franco AR; Dunlop BW; Craighead WE; Mayberg HS
• Pretreatment Resting State fMRI Predicts Differential Response to CBT or Medication
  Volume: 69 Page(s): 165S - 165S
  05/01/2011 Authors: Franco AR; Holtzheimer PE; Kelley ME; Dunlop BW; Craighead WE; Mayberg HS
• Will current socioeconomic trends produce a depressing future for men?
  Br J Psychiatry Volume: 198 Page(s): 167 - 168
  03/01/2011 Authors: Dunlop BW; Mletzko T
• Conceptualizing Treatment Nonadherence in Patients with Bipolar Disorder and PTSD.
  CNS Spectr Volume: 16 Page(s): 11 - 20
  01/01/2011 Authors: Rakofsky JJ; Levy ST; Dunlop BW
• Treating nonspecific anxiety and anxiety disorders in patients with bipolar disorder: a review.
  J Clin Psychiatry Volume: 72 Page(s): 81 - 90
  01/01/2011 Authors: Rakofsky JJ; Dunlop BW
• Concordance between clinician and patient ratings as predictors of response, remission, and recurrence in major depressive disorder.
  J Psychiatr Res Volume: 45 Page(s): 96 - 103
  01/01/2011 Authors: Dunlop BW; Li T; Kornstein SG; Friedman ES; Rothschild AJ; Pedersen R; Ninan P; Keller M; Trivedi MH
• Tolerability of the dexamethasone-corticotropin releasing hormone test in major depressive disorder.
  J Psychiatr Res Volume: 45 Page(s): 24 - 28
  01/01/2011 Authors: Dunlop BW; Betancourt Y; Binder EB; Heim C; Holsboer F; Ising M; McKenzie M; Mletzko T; Pfister H; Nemeroff CB
• An additional consideration for comparisons of antidepressants versus placebo.
  J Clin Psychopharmacol Volume: 30 Page(s): 641 - 642
  10/01/2010 Authors: Dunlop BW
• Should sensitive information from clinical trials be included in electronic medical records?
  JAMA Volume: 304 Page(s): 685 - 686
  08/11/2010 Authors: Dunlop BW
• Test-retest reliability of the SERT imaging agent [11C]HOMADAM in healthy humans
  Volume: 52 Page(s): S110 - S110
  08/01/2010 Authors: Nye JA; Owens MJ; Dunlop B; Jarkas N; Mayberg H; Goodman MM
• Survey of investigators' opinions on the acceptability of interactions with patients participating in clinical trials.
  J Clin Psychopharmacol Volume: 30 Page(s): 323 - 327
  06/01/2010 Authors: Dunlop BW; Vaughan CL
• Correlation between patient and clinician assessments of depression severity in the PREVENT study.
  Psychiatry Res Volume: 177 Page(s): 177 - 183
  05/15/2010 Authors: Dunlop BW; Li T; Kornstein SG; Friedman ES; Rothschild AJ; Pedersen R; Ninan P; Keller M
• Cognitive behavioral analysis system of psychotherapy and brief supportive psychotherapy for augmentation of antidepressant nonresponse in chronic depression: the REVAMP Trial.
  Arch Gen Psychiatry Volume: 66 Page(s): 1178 - 1188
  11/01/2009 Authors: Kocsis JH; Gelenberg AJ; Rothbaum BO; Klein DN; Trivedi MH; Manber R; Keller MB; Leon AC; Wisniewski SR; Arnow BA
• Enhancing informed consent in clinical trials and exploring resistances to disclosing adverse clinical trial results.
  Am J Bioeth Volume: 9 Page(s): 39 - 41
  08/01/2009 Authors: Banja JD; Dunlop B
• Risk of lipid abnormality with haloperidol, olanzapine, quetiapine, and risperidone in a Veterans Affairs population.
  Int Clin Psychopharmacol Volume: 24 Page(s): 204 - 213
  07/01/2009 Authors: Duncan EJ; Woolson SL; Hamer RM; Dunlop BW
• A renewed, ethical defense of placebo-controlled trials of new treatments for major depression and anxiety disorders.
  J Med Ethics Volume: 35 Page(s): 384 - 389
  06/01/2009 Authors: Dunlop BW; Banja J
• Exploratory structural equation modeling of resting-state fMRI: applicability of group models to individual subjects.
  Neuroimage Volume: 45 Page(s): 778 - 787
  04/15/2009 Authors: James GA; Kelley ME; Craddock RC; Holtzheimer PE; Dunlop BW; Nemeroff CB; Mayberg HS; Hu XP
• Assessing rates and predictors of tachyphylaxis during the prevention of recurrent episodes of depression with venlafaxine ER for two years (PREVENT) study.
  Psychopharmacol Bull Volume: 42 Page(s): 5 - 20
  01/01/2009 Authors: Rothschild AJ; Dunlop BW; Dunner DL; Friedman ES; Gelenberg A; Holland P; Kocsis JH; Kornstein SG; Shelton R; Trivedi MH
• Assessing the efficacy of 2 years of maintenance treatment with venlafaxine extended release 75-225 mg/day in patients with recurrent major depression: a secondary analysis of data from the PREVENT study.
  Int Clin Psychopharmacol Volume: 23 Page(s): 357 - 363
  11/01/2008 Authors: Kornstein SG; Kocsis JH; Ahmed S; Thase M; Friedman ES; Dunlop BW; Yan B; Pedersen R; Ninan PT; Li T
• Exercise for depression: efficacy, safety and clinical trial implications.
  Psychopharmacol Bull Volume: 41 Page(s): 65 - 75
  01/01/2008 Authors: Dunlop BW; Self RL
• Combination treatment with benzodiazepines and SSRIs for comorbid anxiety and depression: a review.
  Prim Care Companion J Clin Psychiatry Volume: 10 Page(s): 222 - 228
  01/01/2008 Authors: Dunlop BW; Davis PG
• The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: outcomes from the acute and continuation phases.
  Biol Psychiatry Volume: 62 Page(s): 1371 - 1379
  12/15/2007 Authors: Keller MB; Trivedi MH; Thase ME; Shelton RC; Kornstein SG; Nemeroff CB; Friedman ES; Gelenberg AJ; Kocsis JH; Dunner DL
• Coadministration of modafinil and a selective serotonin reuptake inhibitor from the initiation of treatment of major depressive disorder with fatigue and sleepiness: a double-blind, placebo-controlled study.
  J Clin Psychopharmacol Volume: 27 Page(s): 614 - 619
  12/01/2007 Authors: Dunlop BW; Crits-Christoph P; Evans DL; Hirschowitz J; Solvason HB; Rickels K; Garlow SJ; Gallop RJ; Ninan PT
• The impact of HIPAA authorization on willingness to participate in clinical research.
  Ann Epidemiol Volume: 17 Page(s): 899 - 905
  11/01/2007 Authors: Dunlop AL; Graham T; Leroy Z; Glanz K; Dunlop B
• Tiagabine for social anxiety disorder.
  Hum Psychopharmacol Volume: 22 Page(s): 241 - 244
  06/01/2007 Authors: Dunlop BW; Papp L; Garlow SJ; Weiss PS; Knight BT; Ninan PT
• Two years of maintenance treatment with venlafaxine xr 75-225 mg/d: Efficacy in patients with recurrent unipolar major depression
  EUROPEAN PSYCHIATRY Volume: 22 Page(s): S239 - S240
  03/01/2007 Authors: Kocsis JH; Kornstein SG; Ahmed S; Ferdousi T; Musgnung J; Thase M; Friedman E; Dunlop BW; Yan B; Pedersen R
• The role of dopamine in the pathophysiology of depression.
  Arch Gen Psychiatry Volume: 64 Page(s): 327 - 337
  03/01/2007 Authors: Dunlop BW; Nemeroff CB
• Relative risk of glucose elevation during antipsychotic exposure in a Veterans Administration population.
  Int Clin Psychopharmacol Volume: 22 Page(s): 1 - 11
  01/01/2007 Authors: Duncan E; Dunlop BW; Boshoven W; Woolson SL; Hamer RM; Phillips LS
• Use of dialectical behavior therapy in borderline personality disorder: a view from residency.
  Acad Psychiatry Volume: 31 Page(s): 218 - 224
  01/01/2007 Authors: Sharma B; Dunlop BW; Ninan PT; Bradley R
• Efficacy of two years of maintenance treatment with venlafaxine XR 75 mg/d to 225 mg/d in patients with recurrent unipolar major depression
  Volume: 31 Page(s): S165 - S165
  12/01/2006 Authors: Kocsis J; Kornstein SG; Ahmed S; Ferdousi T; Thase ME; Friedman E; Dunlop BW; Yan B; Pedersen R; Ninan PT
• Psychosocial context of antidepressant response.
  Biol Psychiatry Volume: 57 Page(s): 314
  02/01/2005 Authors: Dunlop BW; Garlow SJ; Ninan PT
• Relapse prevention study of tiagabine in patients with social anxiety disorder
  DEPRESSION AND ANXIETY Volume: 22 Page(s): 223 - 223
  01/01/2005 Authors: Ninan PT; Papp L; Dunlop BW
• Counseling via analogy: improving patient adherence in major depressive disorder.
  Prim Care Companion J Clin Psychiatry Volume: 7 Page(s): 300 - 303
  01/01/2005 Authors: Dunlop BW; Dunlop AL
• Neurobiology and etiology of panic disorder.
  J Clin Psychiatry Volume: 66 Suppl 4 Page(s): 3 - 7
  01/01/2005 Authors: Ninan PT; Dunlop BW
• Effects of risperidone, olanzapine, and typical antipsychotics on random glucose in a VA population
  Volume: 55 Page(s): 189S - 189S
  04/15/2004 Authors: Duncan EJ; Boshoven W; Dunlop B; Henke J; Malpass J; Hamer R; Phillips L
• Disturbed glucose metabolism among patients taking olanzapine and typical antipsychotics
  Volume: 53 Page(s): 46S - 46S
  04/15/2003 Authors: Dunlop BW; Sternberg M; Phillips LS; Andersen J; Duncan EJ
• Disturbed glucose metabolism among patients taking olanzapine and typical antipsychotics.
  Psychopharmacol Bull Volume: 37 Page(s): 99 - 117
  01/01/2003 Authors: Dunlop BW; Sternberg M; Phillips LS; Andersen J; Duncan E
• Assessment of human exposure and human health effects after indoor application of methyl parathion in Lorain County, Ohio, 1995-1996.
  Environ Health Perspect Volume: 110 Suppl 6 Page(s): 1047 - 1051
  12/01/2002 Authors: Rubin C; Esteban E; Kieszak S; Hill RH; Dunlop B; Yacovac R; Trottier J; Boylan K; Tomasewski T; Pearce K